NCT06239155View on ClinicalTrials.gov

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

September 3, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Advanced Solid TumorsHepatocellular Carcinoma
Interventions
DRUG

AST-3424

liquid formulation for Intravenous infusion

Trial Locations (7)

110000

The First Affiliated Hospital of China Medical University, Shenyang

200000

Shanghai East Hospital, Shanghai

210000

Chinese People's Liberation Army Eastern Theater General Hospital Qinhuai medical District, Nanjing

310000

Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

450000

Henan Cancer Hospital, Zhengzhou

510000

Guangdong Qifu Hospital, Guangzhou

Sponsors
All Listed Sponsors
lead

Ascentawits Pharmaceuticals, Ltd

INDUSTRY

NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter